PON1 (Paraoxonase 1) Q192R Gene Polymorphism in North Macedonian Population with Confirmed Coronary Artery Disease
By: K Krsteva Jakimovska, M Vavlukis, A Eftimov and S Topuzovska
References
- Précourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011 Jan;214(1):20–36. doi: 10.1016/j.atherosclerosis.2010.08.076.
- Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991 Jul 29;286(1–2):152–4. doi: 10.1016/0014-5793(91)80962-3.
- Mackness MI, Abbott CA, Arrol S, Durrington PN. The role of highdensity lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993 Sep 15;294:829–34. doi: 10.1042/bj2940829.
- Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993 Dec;104(1–2):129–35. doi: 10.1016/0021-9150(93)90183-u..
- Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995 Dec;96(6):2882–91. doi: 10.1172/JCI118359.
- Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1617–24. doi: 10.1161/01.atv.18.10.1617.
- Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag. 2018;14:137–143. doi: 10.2147/VHRM.S165173
- Jakubowski H. The molecular bases of anti-oxidative and anti-inflammatory properties of paraoxonase 1. Antioxidants (Basel). 2024;13(11):1292. doi: 10.3390/antiox13111292.
- Murillo-González FE, Ponce-Ruiz N, Rojas-García AE, Rothenberg SJ, Bernal-Hernández YY, Cerda-Flores RM, et al. PON1 lactonase activity and its association with cardiovascular disease. Clin Chim Acta. 2020 Jan;500:47–53. doi: 10.1016/j.cca.2019.09.016.
- Mazur A. An enzyme in animal tissues capable of hydrolysing the phosphorus-fluorine bond of alkyl fluorophosphates. J Biol Chem. 1946; 164:271–289.
- Aldridge WN. Serum esterases 2 - An enzyme hydrolysing diethyl p-nitrophenylphosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem. J. 1953; 53:117–124.
- Mackness M, Mackness B. Human Paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015; 567(1):12–21.
- Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem. 2000 Oct 27;275(43):33435–42. doi: 10.1074/jbc.M004543200.
- Taler-Verčič A, Goličnik M, Bavec A. The Structure and Function of Paraoxonase-1 and Its Comparison to Paraoxonase-2 and -3. Molecules. 2020; 25(24):5980. doi: 10.3390/molecules25245980.
- Petrič B, Kunej T, Bavec A. A Multi-Omics Analysis of PON1 Lactonase Activity in Relation to Human Health and Disease. OMICS. 2021; 25(1):38–51. doi:10.1089/omi.2020.0160.
- Najafi M, Gohari LH, Firoozrai M. Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb Res. 2009; 123(3):503–510.
- Ponce-Ruiz N, Murillo-González FE, Rojas-García AE, Mackness M, Bernal-Hernández YY, Barrón-Vivanco BS, et al. Transcriptional regulation of human Paraoxonase 1 by nuclear receptors. Chem Biol Interact. 2017 Apr 25;268:77–84. doi: 10.1016/j.cbi.2017.02.005.
- Sikora M, Bretes E, Perła-Kaján J, Lewandowska I, Marczak Ł, Jakubowski H. Genetic Attenuation of Paraoxonase 1 Activity Induces Proatherogenic Changes in Plasma Proteomes of Mice and Humans. Antioxidants (Basel). 2020 Nov 28;9(12):1198. doi: 10.3390/antiox9121198.
- Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993 Jan;3(1):73–6. doi: 10.1038/ng0193-73.
- Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335–42.
- Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998 Apr 15;101(8):1581–90. doi: 10.1172/JCI1649.
- Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 2004 Feb 28;363(9410):689–95. doi: 10.1016/S0140-6736(04)15642-0.
- Lawlor DA, Day IN, Gaunt TR, Hinks LJ, Briggs PJ, Kiessling M, et al. The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women’s Heart and Health cohort study and a meta-analysis. BMC Genet. 2004 Jun 23;5:17. doi: 10.1186/1471-2156-5-17.
- Pérez-Herrera N, May-Pech C, Hernández-Ochoa I, Castro-Mañé J, Rojas-García E, Borja-Aburto VH, et al. PON1Q192R polymorphism is associated with lipid profile in Mexican men with Mayan ascendancy. Exp Mol Pathol. 2008 Oct;85(2):129–34. doi: 10.1016/j.yexmp.2008.05.003.
- Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, Tavilani H, Pourmotabbed T, Shakiba E, e. et al. Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease. Mol Biol Rep. 2011 Nov;38(8):5421–8. doi: 10.1007/s11033-011-0696-3.
- Ichikawa K, Konta T, Emi M, Toriyama S, Takasaki S, Ikeda A, et al. Genetic polymorphisms of paraoxonase-1 are associated with chronic kidney disease in Japanese women. Kidney Int. 2009 Jul;76(2):183–9. doi: 10.1038/ki.2009.97.
- Costa LG, Cole TB, Vitalone A, Furlong CE. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta. 2005 Feb;352(1–2):37–47. doi: 10.1016/j.cccn.2004.09.019.
- Dounousi E, Bouba I, Spoto B, Pappas K, Tripepi G, Georgiou I, et al. A Genetic Biomarker of Oxidative Stress, the Paraoxonase-1 Q192R Gene Variant, Associates with Cardiomyopathy in CKD: A Longitudinal Study. Oxid Med Cell Longev. 2016;2016:1507270. doi: 10.1155/2016/1507270.
- Scacchi R, Corbo RM, Rickards O, De Stefano GF. New data on the world distribution of paraoxonase (PON1 Gln 192 --> Arg) gene frequencies. Hum Biol. 2003 Jun;75(3):365–73. doi: 10.1353/hub.2003.0049.
- Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 Apr;31(4):811–22. doi: 10.2337/dc08-9018.
- Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21: 473–480.
- Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002 Jul 23;106(4):484–90. doi: 10.1161/01.cir.0000023623.87083.4f.
- Murillo-González FE, Ponce-Ruiz N, Rojas-García AE, Rothenberg SJ, Bernal-Hernández YY, et al. PON1 lactonase activity and its association with cardiovascular disease. Clin Chim Acta. 2020 Jan;500:47–53. doi: 10.1016/j.cca.2019.09.016.
- Shokri Y, Variji A, Nosrati M, Khonakdar-Tarsi A, Kianmehr A, Kashi Z, et al. Importance of paraoxonase 1 (PON1) as an antioxidant and antiatherogenic enzyme in the cardiovascular complications of type 2 diabetes: Genotypic and phenotypic evaluation. Diabetes Res Clin Pract. 2020 Mar;161:108067. doi: 10.1016/j.diabres.2020.108067.
- Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphisms of Paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997;17:1067–73.
- Pati N, Pati U. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int J Cardiol 1998;66:165–8.
- Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Investig 1995;96:3005–8.
- Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265–76.
- Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192Arg) is associated with coronary heart disease in Japanese Non insulin dependent diabetes mellitus. J Clin Endocr Metab. 1997;82:2257–60.
- Rahman N, Zakiullah, Jan A, et al. Association of APOE (rs429358 and rs7412) and PON1 (Q192R and L55M) variants with myocardial infarction in the Pashtun ethnic population of Khyber Pakhtunkhwa, Pakistan. Genes (Basel). 2023;14(3):687. doi: 10.3390/genes14030687.
- Hong SH, Song J, Min WK, Kim JQ. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem. 2001 Sep;34(6):475–81. doi: 10.1016/s0009-9120(01)00257-0.
- Ferré N, Tous M, Paul A, Zamora A, Vendrell JJ, Bardají A, et al. Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem. 2002 May;35(3):197–203. doi: 10.1016/s0009-9120(02)00295-3.
- Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al. The glnArg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998;18:1611–6.
- Robertson KS, Hawe E, Miller GJ, Talmud PJ, Humphries SE; Northwick Park Heart Study II. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta. 2003 Nov 20;1639(3):203–12. doi: 10.1016/j.bbadis.2003.09.008.
- Balcerzyk A, Zak I, Krauze J. Synergistic effects between Q192R polymorphism of paraoxonase 1 gene and some conventional risk factors in premature coronary artery disease. Arch Med Res 2007;38:545–50.
- Darand M, Salehi-Abargouei A, Vahidi Mehrjardi MY, et al. The association of the paraoxonase 1 Q192R polymorphism with coronary artery disease (CAD) and cardiometabolic risk factors in Iranian patients suspected of CAD. Front Cardiovasc Med. 2023;9:1037940. doi: 10.3389/fcvm.2022.1037940.
DOI: https://doi.org/10.2478/bjmg-2025-00018 | Journal eISSN: 2199-5761
Language: English
Page range: 49 - 56
Published on: May 14, 2026
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Related subjects:
© 2026 K Krsteva Jakimovska, M Vavlukis, A Eftimov, S Topuzovska, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.